Heparan sulfate proteoglycan metabolism and the fate of grafted tissues

Advances in Experimental Medicine and Biology

Volumn 865, Issue , 2015, Pages 123-140

  Platt, Jeffrey L ^a   Wrenshall, Lucile E ^b   Johnson, Geoffrey B ^c,d   Cascalho, Marilia ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

Accommodation; Antigen presenting cell; Complement; Dendritic cell; Endothelial cells; Heparan sulfate; Sepsis; Systemic inflammatory response syndrome; Toll like receptor

Indexed keywords

CELL PROTEIN; DAMAGE ASSOCIATED MOLECULAR PATTERN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; PROSTAGLANDIN E2; PROTEOHEPARAN SULFATE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; COMPLEMENT; HEPARAN SULFATE; TLR4 PROTEIN, HUMAN;

ANTIGEN PRESENTING CELL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENDOTHELIUM CELL; GRAFT REJECTION; HEPARAN SULFATE PROTEOGLYCAN METABOLISM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; KIDNEY DEVELOPMENT; KIDNEY GRAFT REJECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MORPHOGENESIS; NEUTROPHIL; ONTOGENY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE ACTIVATION; TISSUE GRAFT; DRUG EFFECTS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKOCYTE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TISSUE TRANSPLANTATION;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DENDRITIC CELLS; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GRAFT REJECTION; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; LEUKOCYTES; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE TRANSPLANTATION; TOLL-LIKE RECEPTOR 4;

EID: 84940367593     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-18603-0_8     Document Type: Article

References (76)

1. Dabek F. 'Car Talk' Brothers Address Graduates. The Tech. 1999;119:1, 16.
2. Platt JL, Rubinstein P. Mechanisms and characteristics of allograft rejection. In: Sabiston Jr DC, Lyerly HK, editors. Textbook of surgery: the biological basis of modern surgical practice. 15th ed. Philadelphia: W.B. Saunders; 1997. p. 400-8.
3. Platt JL, Cascalho M. Transplantation immunology. In: Mulholland MW, Lillemoe KD, Doherty GM, Maier RV, Simeone DM, Upchurch GRJ, editors. Greenfield's surgery: scientific principles and practice. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 497-514.
4. Platt JL, Cascalho M, West LJ. Lessons from cardiac transplantation in infancy. Pediatr Transplant. 2009;13:814-9.
5. Lynch RJ, Silva IA, Chen BJ, Punch JD, Cascalho M, Platt JL. Cryptic B cell response to renal transplantation. Am J Transplant. 2013;13(7):1713-23.
6. Platt JL, LeBien TW, Michael AF. Interstitial mononuclear cell populations in renal graft rejection: identification by monoclonal antibodies in tissue sections. J Exp Med. 1982;155:17-30.
7. Platt JL, Grant BW, Eddy AA, Michael AF. Immune cell populations in cutaneous delayedtype hypersensitivity. J Exp Med. 1983;158:1227-42.
8. Platt JL, LeBien TW, Michael AF. Stages of renal ontogenesis identified by monoclonal antibodies reactive with lymphohemopoietic differentiation antigens. J Exp Med. 1983;157: 155-72.
9. Platt JL, Burke BA, Michael AF. Cellular antigens in nephroblastoma: identification with monoclonal antibodies which recognize hemopoietic cells. Clin Immunol Immunopathol. 1987;43:110-6.
10. Bernfield M, Banerjee SD. The turnover of basal lamina glycosaminoglycan correlates with epithelial morphogenesis. Dev Biol. 1982;90(2):291-305.
11. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998;67:609-52.
12. Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011;3(7):a004952 (1-33).
13. Mikami T, Kitagawa H. Biosynthesis and function of chondroitin sulfate. Biochim Biophys Acta. 2013;1830(10):4719-33.
14. Platt JL, Brown DM, Granlund K, Oegema TR, Klein DJ. Proteoglycan metabolism associated with mouse metanephric development: morphologic and biochemical effects of b-D-xyloside. Dev Biol. 1987;123:293-306.
15. Klein DJ, Brown DM, Moran A, Oegema TR, Platt JL. Chondroitin sulfate proteoglycan synthesis and reutilization of b-D-xyloside initiated chondroitin/dermatan sulfate glycosaminoglycans in fetal kidney branching morphogenesis. Dev Biol. 1989;133:515-28.
16. Klein DJ, Brown DM, Oegema TR, Brenchely PE, Anderson JC, Dickinson MAJ, et al. Glomerular basement membrane proteoglycans are derived from a large precursor. J Cell Biol. 1988;106:963-70.
17. Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL. Role of heparan sulfate in immune systemblood vessel interactions. Immunol Today. 1993;14:500-5.
18. Selvan RS, Ihrcke NS, Platt JL. Heparan sulfate in immune responses. Ann N Y Acad Sci. 1996;797:127-39.
19. Platt JL, Saadi S. The role of complement in transplantation. Mol Immunol. 1999;36:965-71.
20. Saadi S, Wrenshall LE, Platt JL. Regional manifestations and control of the immune system. FASEB J. 2002;16(8):849-56.
21. Platt JL, Trescony P, Lindman BJ, Oegema TR. Heparin and heparan sulfate delimit nephron formation in fetal metanephric kidneys. Dev Biol. 1990;139:338-48.
22. Platt JL, Vercellotti GM, Lindman BJ, Oegema Jr TR, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med. 1990;171(4):1363-8.
23. Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today. 1990; 11:450-6.
24. Key NS, Platt JL, Vercellotti GM. Vascular endothelial cell proteoglycans are susceptible to cleavage by neutrophils. Arterioscler Thromb. 1992;12:836-42.
25. Geller RL, Ihrcke NS, Platt JL. Release of endothelial cell-associated heparan sulfate proteoglycan by activated T cells. Transplantation. 1994;57:770-4.
26. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med. 1995;182:1807-14.
27. Bustos M, Coffman TM, Saadi S, Platt JL. Modulation of eicosanoid metabolism in endothelial cells in a xenograft model: role of cyclooxygenase-2. J Clin Invest. 1997;100:1150-8.
28. Malyguine AM, Saadi S, Holzknecht RA, Patte CR, Sud N, Platt JL, et al. Induction of procoagulant function in porcine endothelial cells by human NK cells. J Immunol. 1997;159: 4659-64.
29. Saadi S, Holzknecht RA, Patte CP, Platt JL. Endothelial cell activation by pore forming structures: pivotal role for IL-1a. Circulation. 2000;101:1867-73.
30. Bustos M, Saadi S, Platt JL. Platelet-mediated activation of endothelial cells: implications for the pathogenesis of transplant rejection. Transplantation. 2001;72:509-15.
31. Ihrcke NS, Parker W, Reissner KJ, Platt JL. Regulation of platelet heparanase during inflammation: role of pH and proteinases. J Cell Physiol. 1998;175:255-67.
32. Ihrcke NS, Platt JL. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell surface molecules. J Cell Physiol. 1996;168:625-37.
33. Saadi S, Platt JL. Endothelial cell responses to complement activation. In: Volanakis JE, Frank MM, editors. The human complement system in health and disease. New York: Marcel Dekker, Inc.; 1998. p. 335-53.
34. Naparstek Y, Cohen IR, Fuks Z, Vlodavsky I. Activated T-lymphocytes produce a matrixdegrading heparan sulfate endoglycosidase. Nature. 1984;310:241-4.
35. Fridman R, Lider O, Naparstek Y, Fuks Z, Vlodavsky I, Cohen IR. Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix. J Cell Physiol. 1987;130:85-92.
36. Raats CJ, Bakker MA, van den Born J, Berden JH. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem. 1997;272(42): 26734-41.
37. Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I, et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest. 1989;83:752-6.
38. Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, et al. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol. 1990;20:493-9.
39. Wrenshall LE, Cerra FB, Carlson A, Bach FH, Platt JL. Regulation of murine splenocyte responses by heparan sulfate. J Immunol. 1991;147:455-9.
40. Wrenshall LE, Carlson A, Cerra FB, Platt JL. Modulation of cytolytic T cell responses by heparan sulfate. Transplantation. 1994;57:1087-94.
41. Wrenshall LE, Cerra FB, Singh RK, Platt JL. Heparan sulfate initiates signals in murine macrophages leading to divergent biological outcomes. J Immunol. 1995;154:871-80.
42. Wrenshall LE, Stevens RB, Cerra FB, Platt JL. Modulation of macrophage and B cell function by glycosaminoglycans. J Leukoc Biol. 1999;66(3):391-400.
43. Steinman RM. Dendritic cells: understanding immunogenicity. Eur J Immunol. 2007;37 Suppl 1:S53-60.
44. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117(5):1195-203.
45. Unanue ER. Antigen presentation in the autoimmune diabetes of the NOD mouse. Annu Rev Immunol. 2014;32:579-608.
46. Kodaira Y, Nair SK, Wrenshall LE, Gilboa E, Platt JL. Phenotypic and functional maturation of dendritic cells modulated by heparan sulfate. J Immunol. 2000;165:1599-604.
47. van Montfoort N, Camps MG, Khan S, Filippov DV, Weterings JJ, Griffith JM, et al. Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A. 2009;106(16):6730-5.
48. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A. 2002;99(1):351-8.
49. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194(6):769-79.
50. Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis. 2008;67 Suppl 3:iii90-6.
51. Frick JS, Grunebach F, Autenrieth IB. Immunomodulation by semi-mature dendritic cells: a novel role of Toll-like receptors and interleukin-6. Int J Med Microbiol. 2010;300(1):19-24.
52. Johnson DJ, Ohashi PS. Molecular programming of steady-state dendritic cells: impact on autoimmunity and tumor immune surveillance. Ann N Y Acad Sci. 2013;1284:46-51.
53. Morelli AE, Thomson AW. Orchestration of transplantation tolerance by regulatory dendritic cell therapy or in-situ targeting of dendritic cells. Curr Opin Organ Transplant. 2014;19(4):348-56.
54. Wrenshall LE, Platt JL. Regulation of T cell homeostasis by heparan sulfate-bound IL-2. J Immunol. 1999;163:3793-800.
55. Wrenshall LE, Platt JL, Elliot TS, Wight TN, Miller JD. Propagation and control of T cell responses by heparan sulfate-bound IL-2. J Immunol. 2003;170:5470-4.
56. Platt JL, Johnson GB, Kodaira Y, Wrenshall LE. Tolerance and the microenvironment. Transplantation. 2001;72:S23-4.
57. Jordan ML, Hoffman RA, Debe EF, West MA, Simmons RL. Prostaglandin E2 mediates subset-specific effects on the functional responses of allosensitized T lymphocyte clones. Transplantation. 1987;43(1):117-23.
58. Brunn GJ, Saadi S, Platt JL. Differential regulation of endothelial cell activation by complement and interleukin 1alpha. Circ Res. 2006;98:793-800.
59. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085-8.
60. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue wellbeing via detection of soluble heparan sulfate by toll-like receptor 4. J Immunol. 2002; 168(10):5233-9.
61. Johnson GB, Brunn GJ, Tang AH, Platt JL. Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol. 2003;24(1):19-24.
62. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest. 2003;111(10):1571-8.
63. Janeway Jr CA, Medzhitov R. Lipoproteins take their toll on the host. Curr Biol. 1999;9(23):R879-82.
64. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135.
65. Rapraeger A, Bernfield M. Cell surface proteoglycan of mammary epithelial cells: protease releases a heparin sulfate-rich extodomain from a putative membrane-associated domain. J Biol Chem. 1985;260:4103-9.
66. Johnson GB, Riggs BL, Platt JL. A genetic basis for the "Adonis" phenotype of low adiposity and strong bones. FASEB J. 2004;18(11):1282-4.
67. Johnson GB, Brunn GJ, Platt JL. An endogenous pathway to systemic inflammatory response syndrome (SIRS)-like responses through toll-like receptor 4. J Immunol (Cutting Edge). 2004;172(1):20-4.
68. Brunn GJ, Wijdicks MF, Platt JL. Toward a modern concept of sepsis: new answers to ancient questions. Discov Med. 2006;6(31):11-7.
69. Brunn GJ, Platt JL. The etiology of sepsis: turned inside out. Trends Mol Med. 2006;12(1):10-6.
70. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013;309(11):1154-62.
71. Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease. J Immunol. 2004;172(9):5143-8.
72. Lynch RJ, Platt JL. Accommodation in organ transplantation. Curr Opin Organ Transplant. 2008;13:165-70.
73. Cascalho MI, Chen BJ, Kain M, Platt JL. The paradoxical functions of B cells and antibodies in transplantation. J Immunol. 2013;190(3):875-9.
74. Koch CA, Khalpey ZI, Platt JL. Humoral immunity in xenotransplantation: B-cell tolerance and accommodation. Curr Opin Organ Transplant. 2004;9(2):170-5.
75. Koch CA, Kanazawa A, Nishitai R, Knudsen BE, Ogata K, Plummer TB, et al. Intrinsic resistance of hepatocytes to complement-mediated injury. J Immunol. 2005;174:7302-9.
76. Williams JM, Holzknecht ZE, Plummer TB, Lin SS, Brunn GJ, Platt JL. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation. 2004;78(10):1471-8.